• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    K

    Kakatiya Medical College

    311论文总数
    1,746引用总数

    The Kakatiya Medical College (KMC) is one of the medical schools of Telangana, located in Warangal under the gamut of Kaloji Narayana Rao University of Health Sciences and the Medical Council of India (MCI).

    论文量&引用量时间轴

    机构学者

    论文(311)

    年份
    起
    –
    止
    排序
    1Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonist and SGLT2 Inhibitor Combination Therapy Versus SGLT2-inhibitor Monotherapy in Patients with Chronic Kidney Disease with Albuminuria: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Khubaib Mohammad Murtafa,Sadiya Sajad Khanday,Rohit Vondivillu Srinivasan,Mir Wajid Majeed, Hasindu Avishka Arumapperuma, Arjun Anilkumar,Shahrukh Mohammed, Muhammad Rahim Arshad, Merruna Liqua Chishti, Suhaib Andrabi

    Sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors) and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) exert complementary renoprotective effects in chronic kidney disease (CKD). However, the efficacy and safety of nsMRA plus SGLT2 inhibitor combination therapy compared with SGLT2 inhibitor monotherapy in patients with albuminuria remain uncertain. We systematically searched for randomized controlled trials (RCTs) comparing nsMRA plus SGLT2 inhibitor therapy with SGLT2 inhibitor monotherapy in adults with CKD with albuminuria. Outcomes included changes in albumin-creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), serum potassium, categorical ACR response (≥ 30

    2026International Urology and Nephrology(2026)引用:23
    引用
    AI阅读
    加入学术空间
    2Nationwide Mortality Trends for Non-Alcoholic Fatty Liver Disease and Diabetes Mellitus in the U.S. (1999–2022): Insights from the CDC WONDER Database
    Muhammad Faizan Ali, Husnain Ahmad, Arun Kumar Maloth, Harsh Kumar, Youssef Ramadan, Mahnoor Saeed Malik,Talha Qadeer, Muhammad Khan, Muneeb Shad Mohmand, Simran Joshi,Zarwa Rashid, Abdelrhman H. Mohamed,

    Non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus (DM) are increasingly prevalent, interrelated conditions contributing significantly to morbidity and mortality. Understanding long-term mortality trends is essential to guide public health strategies. This study aimed to evaluate nationwide mortality trends involving NAFLD and DM in the United States from 1999 to 2022 and to assess demographic and geographic disparities. CDC WONDER was used to extract data for adults aged ≥ 25 years. 10th Revision (ICD−10), using the explicit codes with K74.0, K74.6, K75.8, K76.0 and K76.9 for NAFLD and E10-E14 for DM. Age- Adjusted Mortality Rates (AAMRs) per million population were calculated and trends were analyzed by calculating annual percent change (APC) and the average annual percent change (AAPC) using Joinpoint Regression Program (version 5.2.0.0; National Cancer Institute), with statistical significance set at p < 0.05. From 1999 to 2022, a total of 126,431 NAFLD and DM related deaths were recorded with most of the deaths occurring in Medical Facilities (43.52

    2026Journal of Diabetes & Metabolic Disorders(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Dual-targeting Strategies for Cancer and Diabetes: Converging Pharmacological Pathways and Repurposed Therapies.
    Gurjit Kaur Bhatti, Ishtiaq Ahmed, Abhishek Sehrawat,Pushpender Kumar Sharma,Ramesh Kandimalla, Kawaljit Singh Kaura,Jasvinder Singh Bhatti

    The rising global burden of cancer and diabetes mellitus, particularly type 2 diabetes (T2DM), underscores a critical need for integrated therapeutic strategies. Epidemiological studies reveal a compelling bidirectional association between these diseases, with T2DM increasing cancer risk and adversely affecting cancer prognosis. Shared pathophysiological mechanisms including insulin/IGF-1 signaling, chronic low-grade inflammation, oxidative stress, and metabolic reprogramming serve as potential therapeutic convergence points. This review explores the mechanistic and clinical basis for dual-targeting strategies that address both malignancy and metabolic dysfunction simultaneously. Key molecular intersections include the PI3K/Akt/mTOR and AMPK pathways, which are central to cell proliferation, survival, and glucose metabolism. Pharmacological agents like metformin, SGLT2 inhibitors, and statins demonstrate promising anticancer effects in addition to glycemic control, while biologics such as canakinumab and tocilizumab modulate inflammatory processes relevant to both disease states. Natural compounds including curcumin, resveratrol, and berberine exhibit dual benefits via antioxidant, anti-inflammatory, and metabolic pathways. The review critically evaluates preclinical studies, retrospective cohort analyses, and clinical trial data supporting the repurposing of anti-diabetic agents for oncology indications. Despite mixed outcomes in large-scale trials, evidence suggests biomarker-based patient selection may enhance therapeutic efficacy. Moreover, emerging paradigms including immunometabolism, gut microbiota modulation, and gene-based interventions offer promising frontiers for integrated care. Ultimately, dual-targeting strategies represent an emerging and promising therapeutic framework for managing patients with overlapping cancer and metabolic disease, with potential to optimize outcomes, reduce therapy-related toxicities, improve long-term survival. Future research must prioritize biomarker-guided precision therapies, multidisciplinary management and the inclusion of metabolic parameters in oncology trial designs.

    2026Molecular aspects of medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies
    Sai Kiran Kuchana, Uday Kumar Repalle, Nikhilesh V Alahari, Manpreet Kondamuri, Sai Kiran Manduva, Raghu Vamsi Vanguru, Sri Anjali Gorle, Suresh K Alahari

    BACKGROUND:Artificial intelligence (AI) is reshaping oncology at every stage of the cancer care pathway, from population-level screening through molecular diagnosis, treatment planning, and post-treatment surveillance. Despite an exponential growth in AI oncology publications exceeding 5000 peer-reviewed studies annually, a critical and persistent gap separates demonstrated algorithmic performance from genuine patient benefit. Most published evidence derives from retrospective, single-institution studies conducted in curated dataset environments that systematically differ from real-world clinical deployment conditions. This comprehensive review examines the translational maturity of AI applications across 18 major malignancies, providing an evidence-stratified, cross-cancer assessment of where AI has fulfilled, approaches, or remains far from fulfilling its transformative potential in oncological care. METHODS:A structured narrative review was conducted across PubMed/MEDLINE, Embase, IEEE Xplore, and the Cochrane Library, supplemented by regulatory grey literature including FDA 510(k) decision summaries, CE Technical Files, and ClinicalTrials.gov. Search terms combined cancer site-specific terminology with AI methodology terms and translational outcome descriptors. Studies were only included if they applied an AI or machine learning methodology to a defined clinical oncological task, reported a clearly specified performance evaluation, and involved human subjects or human-derived clinical data. Evidence quality was assessed using QUADAS-2, PROBAST, and Cochrane RoB 2. A five-tier translational readiness framework, grounded in the NIH T0-T4 translational spectrum and CONSORT-AI/SPIRIT-AI guidelines, was applied a priori to enable cross-cancer comparison. A rigorous distinction was maintained between diagnostic accuracy and clinical utility, defined as demonstrated impact on clinical decision-making or patient-centered outcomes. RESULTS:Across all 18 malignancies, AI development varied profoundly by cancer type. Breast cancer and prostate cancer (Tier 1) represent the most mature AI ecosystems, with multiple FDA-cleared tools for mammographic screening and digital pathology achieving prospective multi-institutional validation; however, randomized evidence demonstrating reduced cancer-specific mortality remains absent. Lung, hepatocellular, and melanoma AI (Tier 2) have achieved regulatory milestones but face documented performance disparities across demographic subgroups, including DermaSensor's 20.7% specificity in primary care settings and HCC model failures in non-viral disease etiologies. Colorectal, glioma, pancreatic, and ovarian cancers (Tier 3) exhibit technical maturity without clinical clarity: colorectal CADe systems increase adenoma detection but meta-analyses of 18,232 patients across 21 RCTs fail to demonstrate improvement in advanced neoplasia detection or cancer incidence reduction. A full study-level presentation of pooled estimates, confidence intervals, and heterogeneity statistics for each cited randomized evidence base across all cancer types would extend beyond the intended scope and format of this cross-cancer narrative review. Gastric, esophageal, cervical, bladder, head and neck, and endometrial cancers (Tier 4) demonstrate promising single-institutional or geographically restricted results without multi-institutional external validation, particularly notable for cervical cancer AI's transformative potential in low- and middle-income countries constrained by absent regulatory frameworks. Hematologic malignancies, sarcoma, and pediatric solid tumors (Tier 5) face structural barriers, workflow incompatibility in hematopathology, extreme rarity in sarcoma (>70 subtypes, <15,000 US cases annually), and irreducible ethical constraints in pediatric data governance, that cannot be resolved through algorithmic refinement alone. CONCLUSIONS:Oncological AI has not yet fulfilled its clinical promise. Across all five translational tiers, a single finding is consistent: diagnostic accuracy is not a surrogate for patient benefit. AI tools with high sensitivity and specificity have repeatedly failed to demonstrate equivalent reductions in cancer-specific mortality, overdiagnosis, or procedural harm under real-world outcome scrutiny. Simultaneously, documented performance disparities across races, ethnicity, disease etiology, and geographic setting reveal that current AI systems risk amplifying the very health inequities they are positioned to resolve. Bridging this translational gap requires three coordinated systemic shifts: regulatory frameworks mandating post-market outcome surveillance as a condition of clinical clearance; prospective trial designs measuring patient-centered endpoints rather than diagnostic concordance alone; and sustained infrastructure investment in federated data governance, demographically inclusive training datasets, and LMIC-accessible regulatory pathways. AI holds genuine potential to reduce cancer mortality on a global scale-but only if held to the evidentiary and equity standards that the stakes of oncological care demand.

    2026Cancers(2026)
    引用
    AI阅读
    加入学术空间
    5Temporal Trends and Mortality Burden of AKI Complicated by Sepsis in the United States: A 25-Year Retrospective Analysis, 1999-2024
    Farkhanda Maqbool,Dileep Raja Kuraku, Laxmi Prasanna Bandi,Nagarjuna Keshapogu,Kashf Younas,Karthik Kanna Venkatesh,Tarun Nallagonda,Achyuth Balla,Ragav Vikraman Thiyagarajan,Sricharan Chiluveru, Nabiha Khan,Sai Jahnu Sree Reddy Narla,
    2026Journal of the American Society of Nephrology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 311 篇论文

    合作机构(100)

    Dow University of Health Sciences合作论文 19
    Kakatiya University合作论文 13
    Government Medical College,University of Kashmir合作论文 13
    King Edward Medical University合作论文 7
    克什米尔大学合作论文 7
    Kaloji Narayana Rao University of Health Sciences合作论文 7
    贾达普大学合作论文 7
    All India Institute of Medical Sciences合作论文 7
    Osmania Medical College,Kaloji Narayana Rao University of Health Sciences合作论文 7
    亚历山大大学合作论文 6

    机构统计